Search the Newsreel

Deutsche Bank Aktiengesellschaft Reiterates Sell Rating for Antofagasta (LON:ANTO)

Deutsche Bank Aktiengesellschaft has reissued a "sell" rating for Antofagasta (LON:ANTO), setting a price target of GBX 3,400, which suggests a potential downside of 5.92%. This rating contributes to an overall "Reduce" consensus among analysts, with an average price target of GBX 3,843.75. The …

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

C4 Therapeutics (CCCC) gains 6.9% disclosed stake from Squadron Master Fund

Squadron Master Fund LP and related entities have disclosed a 6.9% beneficial ownership stake in C4 Therapeutics (CCCC), totaling 7,600,000 shares. This includes 7,200,000 common shares and 400,000 shares underlying currently exercisable long call options. The filing indicates shared voting and dispositive powers among …

Coeur Mining, Inc. $CDE Shares Sold by NewEdge Advisors LLC

NewEdge Advisors LLC significantly reduced its stake in Coeur Mining (NYSE:CDE) by 60% in the first quarter, selling 172,952 shares and retaining 115,143 shares. Despite this, institutional investors collectively own 63.01% of the company. Coeur Mining reported quarterly earnings that missed analyst expectations, though …

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen has downgraded Protara Therapeutics (NASDAQ:TARA) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy" with an average price target of $26.25. The company's shares were trading at $3.97, near their 52-week low, after reporting …

NewEdge Advisors LLC Raises Stake in Weyerhaeuser Company $WY

NewEdge Advisors LLC significantly increased its stake in Weyerhaeuser Company (NYSE:WY) by 317.4% in the first quarter, now holding 89,800 shares valued at $2.19 million. Institutional investors collectively own a substantial 82.99% of the company. Weyerhaeuser reported strong Q1 earnings, surpassing analyst estimates with …

Assenagon Asset Management S.A. Sells 216,061 Shares of Keurig Dr Pepper, Inc $KDP

Assenagon Asset Management S.A. significantly reduced its stake in Keurig Dr Pepper (NASDAQ:KDP) by 82.7% in the second quarter, selling 216,061 shares. Following the sale, the firm now owns 45,040 shares valued at $1.47 million. Other institutional investors have shown mixed activity, with some …

Marathon Petroleum (NYSE:MPC) Presents a Compelling Value Opportunity

Marathon Petroleum (NYSE:MPC) appears to be a compelling value opportunity, scoring high on valuation with a P/E ratio significantly lower than industry and S&P 500 averages, and strong expected earnings growth. While its profitability is good and financial health adequate despite some leverage, its …

Cambiar Investors LLC Purchases 55,769 Shares of Weyerhaeuser Company $WY

Cambiar Investors LLC increased its stake in Weyerhaeuser Company (NYSE:WY) by 5.3% in the second quarter, acquiring an additional 55,769 shares. This brings their total holdings to 1.10 million shares, valued at approximately $26.3 million. Weyerhaeuser also reported beating quarterly earnings expectations with adjusted …

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Candel Therapeutics (NASDAQ:CADL) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $19.29, significantly above its current trading price of $11.72. Despite recent insider share sales and a larger-than-expected quarterly loss of $0.52 per share, analysts maintain …

Milestone’s FDA Win Now Faces A Tougher Test: Sales

Milestone Pharmaceuticals (NASDAQ: MIST) recently gained FDA approval for its lead product, CARDAMYST™ (etripamil) nasal spray, for PSVT. However, the company now faces the challenge of commercializing the product, with early sales and market sentiment being mixed. The success of CARDAMYST depends heavily on …

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Enliven Therapeutics (NASDAQ:ELVN) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $72.67. This comes despite the company reporting a wider-than-expected quarterly loss of $0.49 per share. Recent insider selling, including a director's $9.6 million sale, has …

KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock information for Kailera Therapeutics, Inc. (KLRA), including its real-time price, key market data like market cap and trading volume, and historical performance trends. It details how to buy KLRA stock on the MEXC exchange and offers an overview of …

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

Silence Therapeutics closes $201.3M public offering By Investing.com

Silence Therapeutics plc (NASDAQ:SLN) has successfully closed an underwritten public offering, raising approximately $201.3 million. The offering included 14,907,407 American Depositary Shares at $13.50 per ADS, with underwriters fully exercising their option for additional shares. The gross proceeds will support the clinical-stage biotechnology company …

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Coeur Mining, Inc. $CDE Shares Sold by Handelsbanken Fonder AB

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Handelsbanken Fonder AB Reduces Stock Holdings in Weyerhaeuser Company $WY

Handelsbanken Fonder AB reduced its stake in Weyerhaeuser Company (NYSE:WY) by 17.9% in the second quarter, selling 48,885 shares and retaining 223,900 shares valued at $5.36 million. Despite the reduction, institutional investors collectively own 82.99% of Weyerhaeuser. The company reported strong quarterly earnings, beating …

National Energy Services Reunited (NESR), Why Is It Back In The Spotlight?

National Energy Services Reunited (NESR) is gaining attention after strong Q2 2026 earnings, increased sales, and new contracts in the Middle East. The company's stock price has shown significant momentum, with a 90-day return of 42.62%. While a valuation model suggests the stock is …

XS3324770646 Bond Yield and Price — LUXSE:XS3324770646

This article provides detailed information on the Deutsche Bank Aktiengesellschaft 4.6% 13-AUG-2031 bond, identified by ISIN XS3324770646, traded on the Luxembourg Stock Exchange. It covers key terms such as outstanding amount, face value, coupon rate, and maturity date, along with issuer details and a …

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts

Gain Therapeutics (NASDAQ:GANX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.50. The company recently reported a narrower-than-expected quarterly loss of $0.11 per share. Institutional investors hold a significant portion of GANX stock, with several firms …

Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average "Moderate Buy" rating from sixteen research firms, with an average 12-month price target of $11.77. Despite this bullish sentiment from analysts, the company's shares are trading down 0.4% at $2.25, and it reported a quarterly loss …

Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN

Vistagen Therapeutics (VTGN) announced a non-dilutive financing of up to $100 million with HealthCare Royalty Partners. This agreement extends the company's financial runway into 2027, allowing it to advance its late-stage clinical programs. The initial $50 million will support the Phase 3 PALISADE-2 trial …

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Viking Therapeutics Inc (VKTX) News, Articles, Events & Latest Updates

Euro India Fresh Foods Ltd is Rated Sell

Are Capricor Therapeutics’ (CAPR) Rising Losses Reframing the Risk-Reward Balance of Its Pipeline Strategy?

Liquidity Mapping Around (APGE) Price Events

This article provides a detailed liquidity mapping analysis for Apogee Therapeutics Inc. (NASDAQ: APGE), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines institutional trading strategies including long, momentum breakout, and short positions with specific entry, target, and stop-loss levels. …

T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G

T. Rowe Price Associates, Inc. has disclosed a 5.2% beneficial ownership stake in Viridian Therapeutics, Inc. (VRDN) through a Schedule 13G SEC filing. As of June 30, 2026, the firm holds 5,748,426 shares of common stock, with sole voting power over 5,748,380 shares and …